Vimentin Antibody (VM452) [DyLight 488]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-33060G
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Validated:
Human, Porcine, Bovine, Canine, Chicken, Feline, Goat, Mouse (Negative), Rat (Negative)
Applications
Flow Cytometry, Immunohistochemistry-Paraffin, Knockout Validated, Protein Array, Western Blot
Label
DyLight 488 (Excitation = 493 nm, Emission = 518 nm)
Antibody Source
Monoclonal Mouse IgG1 kappa Clone # VM452
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for Vimentin Antibody (VM452) [DyLight 488]
Immunogen
Recombinant full-length human vimentin protein (Uniprot: P08670)
Reactivity Notes
Does not react with Mouse or Rat.
Localization
Cytoplasmic
Specificity
This monoclonal antibody reacts with a 58kDa protein identified as Vimentin. It shows no cross-reaction with other closely related intermediate filament proteins (IFP however, when used in panels with other antibodies, it is useful for the sub-classification of a given tumor. Expression of Vimentin, when used in conjunction with anti-keratin, is helpful when distinguishing melanomas from undifferentiated carcinomas and large cell lymphomas. All melanomas and Schwannomas react strongly with anti-Vimentin. It labels a variety of mesenchymal cells, including melanocytes, lymphocytes, endothelial cells, and fibroblasts. Non-reactivity of anti-Vimentin is often considered more useful than its positive reactivity, since there are a few tumors that do not contain Vimentin, e.g. hepatoma and seminoma. Anti-Vimentin is also useful as a tissue process control reagent.
Marker
Mesenchymal Cell Marker
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1 kappa
Description
This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.
Applications for Vimentin Antibody (VM452) [DyLight 488]
Application
Recommended Usage
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry-Paraffin
Optimal dilutions of this antibody should be experimentally determined.
Knockout Validated
Optimal dilutions of this antibody should be experimentally determined.
Protein Array
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: Vimentin
Activated macrophages have been shown to secrete phosphorylated vimentin which can be stimulated by a variety of pathophysiological factors including oxidized low-density lipoproteins and TNF-alpha or inhibited by IL-10 (1). The vimentin protein is often expressed at the cell surface playing a role in cell-cell interactions, tissue damage and repair, immune response, and pathogen recognition (1). Vimentin functions in many cytoskeletal processes including cell migration, which is highlighted by its upregulation during epithelial-to-mesenchymal transition (EMT) (4,5). Vimentin is a commonly used marker for EMT and is expressed by many tumor types (5). For example, high metastasis of oral squamous cell carcinomas also showed high vimentin positive expression in immunohistochemical staining analysis (5). A number of vimentin targeting compounds are in cancer-related clinical trials, however, given the multifunctional role of vimentin, the effect of inhibition on non-malignant cells needs to be thoroughly examined (5).
References
1. Ramos, I., Stamatakis, K., Oeste, C. L., & Perez-Sala, D. (2020). Vimentin as a Multifaceted Player and Potential Therapeutic Target in Viral Infections. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21134675
2. Uniprot (P08670)
3. Morrow, C. S., & Moore, D. L. (2020). Vimentin's side gig: Regulating cellular proteostasis in mammalian systems. Cytoskeleton (Hoboken, N.J.). https://doi.org/10.1002/cm.21645
4. van Bodegraven, E. J., & Etienne-Manneville, S. (2020). Intermediate filaments against actomyosin: the david and goliath of cell migration. Current Opinion in Cell Biology. https://doi.org/10.1016/j.ceb.2020.05.006
5. Strouhalova, K., Prechova, M., Gandalovicova, A., Brabek, J., Gregor, M., & Rosel, D. (2020). Vimentin Intermediate Filaments as Potential Target for Cancer Treatment. Cancers. https://doi.org/10.3390/cancers12010184
Alternate Names
VIM
Gene Symbol
VIM
Additional Vimentin Products
Product Documents for Vimentin Antibody (VM452) [DyLight 488]
Product Specific Notices for Vimentin Antibody (VM452) [DyLight 488]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...